File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study

TitleAllogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study
Authors
Issue Date2010
PublisherB M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/
Citation
Annals Of The Rheumatic Diseases, 2010, v. 69 n. 8, p. 1423-1429 How to Cite?
AbstractObjective: To determine the safety and efficacy of allogeneic mesenchymal stem cell transplantation (MSCT) in refractory systemic lupus erythematosus (SLE). Methods: A total of 15 patients with persistently active SLE underwent MSCT. Outcome was evaluated by changes in the SLE disease activity index (SLEDAI), serological features (anti-nuclear antibodies and antidouble-stranded DNA (anti-dsDNA)), renal function and percentage of peripheral blood regulatory T cells. Results: From 11 March 2007 to 4 November 2008, 15 patients with persistently active SLE were enrolled and underwent MSCT. The mean follow-up period was 17.2±9.5 months. A total of 13 patients have been followed for more than 12 months. All patients clinically improved following treatment with mesenchymal stem cells with a marked decrease in the SLEDAI score and 24 h proteinuria. At 12-month follow-up, SLEDAI scores decreased from 12.2±3.3 to 3.2±2.8 and proteinuria decreased from 2505.0±1323.9 to 858.0±800.7 mg/24 h (all p<0.05, by paired t test, n=12). At 1-year follow-up in 13 patients, 2 had a relapse of proteinuria, while the other 11 continue to have decreased disease activity on minimal treatment. Anti-dsDNA levels decreased. Improvement in glomerular filtration rate was noted in two patients in which formal testing was performed. Non-renal-related manifestations also improved significantly. No serious adverse events were reported. Conclusion: Allogeneic MSCT in patients with refractory lupus resulted in amelioration of disease activity, improvement in serological markers and stabilisation of renal function. MSCT appears beneficial in treatment of patients with SLE refractory to conventional treatment options.
Persistent Identifierhttp://hdl.handle.net/10722/129504
ISSN
2015 Impact Factor: 12.384
2015 SCImago Journal Rankings: 4.537
ISI Accession Number ID
Funding AgencyGrant Number
National Natural Science Foundation of China30972736
30772014
Jiangsu Province Science and Technology Achievement Transformation FoundationBA2009124
Chinese National 115 Supporting Program2008BAI59B02
Jiangsu Province Natural Science FoundationBK2009034
Jiangsu Province 135 Talent FoundationRC2007002
Jiangsu Province 'Six Summit Talent' Foundation
Nanjing Health Bureau Young Scientists Launching ProjectQYK09174
National 115 Supporting Program2008BAI59B02
Funding Information:

This study was supported by grants from the National Natural Science Foundation of China (no. 30972736, 30772014); Jiangsu Province Science and Technology Achievement Transformation Foundation (BA2009124); Chinese National 115 Supporting Program (2008BAI59B02); Jiangsu Province Natural Science Foundation (BK2009034); Jiangsu Province 135 Talent Foundation (RC2007002); Jiangsu Province 'Six Summit Talent' Foundation and Nanjing Health Bureau Young Scientists Launching Project (QYK09174).

References

 

DC FieldValueLanguage
dc.contributor.authorLiang, Jen_HK
dc.contributor.authorZhang, Hen_HK
dc.contributor.authorHua, Ben_HK
dc.contributor.authorWang, Hen_HK
dc.contributor.authorLu, Len_HK
dc.contributor.authorShi, Sen_HK
dc.contributor.authorHou, Yen_HK
dc.contributor.authorZeng, Xen_HK
dc.contributor.authorGilkeson, GSen_HK
dc.contributor.authorSun, Len_HK
dc.date.accessioned2010-12-23T08:38:13Z-
dc.date.available2010-12-23T08:38:13Z-
dc.date.issued2010en_HK
dc.identifier.citationAnnals Of The Rheumatic Diseases, 2010, v. 69 n. 8, p. 1423-1429en_HK
dc.identifier.issn0003-4967en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129504-
dc.description.abstractObjective: To determine the safety and efficacy of allogeneic mesenchymal stem cell transplantation (MSCT) in refractory systemic lupus erythematosus (SLE). Methods: A total of 15 patients with persistently active SLE underwent MSCT. Outcome was evaluated by changes in the SLE disease activity index (SLEDAI), serological features (anti-nuclear antibodies and antidouble-stranded DNA (anti-dsDNA)), renal function and percentage of peripheral blood regulatory T cells. Results: From 11 March 2007 to 4 November 2008, 15 patients with persistently active SLE were enrolled and underwent MSCT. The mean follow-up period was 17.2±9.5 months. A total of 13 patients have been followed for more than 12 months. All patients clinically improved following treatment with mesenchymal stem cells with a marked decrease in the SLEDAI score and 24 h proteinuria. At 12-month follow-up, SLEDAI scores decreased from 12.2±3.3 to 3.2±2.8 and proteinuria decreased from 2505.0±1323.9 to 858.0±800.7 mg/24 h (all p<0.05, by paired t test, n=12). At 1-year follow-up in 13 patients, 2 had a relapse of proteinuria, while the other 11 continue to have decreased disease activity on minimal treatment. Anti-dsDNA levels decreased. Improvement in glomerular filtration rate was noted in two patients in which formal testing was performed. Non-renal-related manifestations also improved significantly. No serious adverse events were reported. Conclusion: Allogeneic MSCT in patients with refractory lupus resulted in amelioration of disease activity, improvement in serological markers and stabilisation of renal function. MSCT appears beneficial in treatment of patients with SLE refractory to conventional treatment options.en_HK
dc.languageengen_US
dc.publisherB M J Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/en_HK
dc.relation.ispartofAnnals of the Rheumatic Diseasesen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAntibodies, Antinuclear - blood-
dc.subject.meshLupus Erythematosus, Systemic - immunology - therapy-
dc.subject.meshMesenchymal Stem Cell Transplantation - adverse effects - methods-
dc.titleAllogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0003-4967&volume=69&issue=8&spage=1423&epage=1429&date=2010&atitle=Allogenic+mesenchymal+stem+cells+transplantation+in+refractory+systemic+lupus+erythematosus:+A+pilot+clinical+study-
dc.identifier.emailLu, L:liweilu@hkucc.hku.hken_HK
dc.identifier.authorityLu, L=rp00477en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1136/ard.2009.123463en_HK
dc.identifier.pmid20650877-
dc.identifier.scopuseid_2-s2.0-77955451557en_HK
dc.identifier.hkuros176945en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77955451557&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume69en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1423en_HK
dc.identifier.epage1429en_HK
dc.identifier.isiWOS:000280171700004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.citeulike7929918-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats